Hello everyone. I hope this message finds you well. Ai Ken Pharma has finally seen the strategic transformation initiated two years ago gain traction, and we achieved significant growth in our strategic focus areas of oncology and gastrointestinal surgery in 2024. I would like to extend my heartfelt gratitude to our partners for their invaluable support in providing clinical and academic information and organizing seminars.

Additionally, we have signed an exclusive distributorship agreement in Laos and Cambodia with Gunze Medical, a leading Japanese company in the field of biomaterials (absorbable tissue reinforcement materials). Together, we aim to pioneer the introduction of innovative surgical treatments in these countries.

Ai Ken Pharma Laos

Ai Ken Pharma Laos celebrated its 8th anniversary on October 10, 2024. Laos continues to face economic stagnation due to the foreign currency shortage and inflation crisis that began in 2022. Assuming these challenges will persist for the next five years, we are formulating strategies accordingly. While we exited the generic pharmaceutical business two years ago, the acquisition of Unison by B.Grimm brought a request from their new management team to resume operations in Laos. This strategic decision reflects the current and future economic outlook in Laos.

Our key products, such as the anti-cancer drug TS-ONE, amino acid supplements Livact and Amiyu, liver protectant MinoPhagen, and amino acid infusions Kidomin and Amiparen, continue to show steady growth.

In January, we held Gunze Medical’s launch event, the “1st Laos Biomaterial Meeting,” with great success. The event attracted 80 gastrointestinal and plastic surgeons from Laos, with three prominent speakers from Japan delivering lectures online. While this treatment method is still new, Ai Ken Pharma Laos is committed to providing advanced information to medical professionals to establish it as the standard in Laos within the next decade.

Ai Ken Pharma Cambodia

Ai Ken Pharma Cambodia marked its 6th anniversary on July 14, 2024. Cambodia’s economy continues to grow steadily, achieving the second-highest growth rate in ASEAN at 6% in 2024. We aim to outpace this economic growth by focusing our activities on institutions like Calmette Hospital and the National Cancer Center.

The treatment method combining Lonsurf (+Bevacizumab), already a standard in Western countries due to outstanding clinical trial results, has been adopted by the Cambodian National Cancer Center and is now widely used. Additionally, the amino acid supplement Livact, featured in Japanese and Thai guidelines, is becoming a standard adjunctive treatment for liver cancer at the National Cancer Center.

Under the new health policies of Prime Minister Hun Manet, Cambodia aims to achieve an 80% health insurance coverage rate by 2030. Led by GM Thearath, our Cambodian team is committed to advancing clinical research, providing high-quality information to medical professionals, and ensuring our products contribute to improving the lives of Cambodian patients.

Ai Ken Pharma Asia Pacific Holdings Strategy

At the end of 2024, we established Ai Ken Pharma Asia Pacific Holdings in Singapore, designating it as our Asia headquarters and making Laos and Cambodia its subsidiaries. Responding to strong client demand, we are moving forward with strategic initiatives, including potential expansion to other ASEAN countries.

With the slogan “One Asia, One Ai Ken” and the vision of “A Japanese Bridge for Healthcare Needs in Asia”, we aim to establish a trusted brand presence and provide meticulous services that make Ai Ken Pharma synonymous with healthcare excellence in ASEAN.

Looking forward to the next 10, 20, and 50 years, Ai Ken Pharma will continue to embrace challenges to bring satisfaction and value to both our clients and customers.

Kentaro Imamoto,
Founder, President and CEO
Ai Ken Pharma Asia Pacific Holdings Pte.Ltd